/Bristol-Myers%20Squibb%20Co_%20NJ%20office-by%20Amy%20Lutz%20via%20Shutterstock.jpg)
Bristol-Myers Squibb Company (BMY) is one of the leading biopharmaceutical companies focused on developing treatments for diseases like cancer, inflammatory, immunologic, cardiovascular, or fibrotic diseases. With a market cap of $95.4 billion, Bristol-Myers’ operations span various countries in the Americas, Europe, and the Indo-Pacific.
The healthcare giant is expected to announce its second-quarter results before the market opens on Thursday, Jul. 31. Ahead of the event, analysts expect BMY to deliver a profit of $1.38 per share, down 33.3% from $2.07 per share reported in the year-ago quarter. On a positive note, the company has a solid earnings surprise history and has surpassed the Street’s bottom-line estimates in each of the past four quarters.
For the full fiscal 2025, analysts expect BMY to deliver an EPS of $6.56, significantly up from $1.15 reported in the previous year. While in fiscal 2026, its earnings are expected to drop 8.1% year-over-year to $6.03 per share.
BMY stock prices have gained nearly 15% over the past 52 weeks, outpacing the S&P 500 Index’s ($SPX) 12.1% gains and the Health Care Select Sector SPDR Fund’s (XLV) 8.3% decline during the same time frame.
Bristol-Myers Squibb’s stock prices observed a marginal uptick in the trading session after the release of its better-than-expected Q1 results on Apr. 24. Due to a drop in US sales and currency headwinds faced in foreign markets, the company’s overall topline for the quarter dropped 5.6% year-over-year to $11.2 billion. However, these figures surpassed the Street’s expectations by a notable margin. Meanwhile, the company reported an adjusted net income of $3.7 billion, up from the $8.2 billion loss reported in the year-ago quarter. Moreover, its adjusted EPS of $1.80 surpassed the consensus estimates by 19.2%.
The stock holds a consensus “Moderate Buy” rating overall. Of the 26 analysts covering the BMY stock, opinions include seven “Strong Buys,” 18 “Holds,” and one “Strong Sell.” Its mean price target of $56.05 suggests a 19.6% upside potential from current price levels.
